PDCO minutes of the 24-27 March 2026 meeting

8 May 2026

PRIME: priority medicines

8 May 2026

PSUSA/00001232/202507

8 May 2026

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 April 2026

8 May 2026

List of medicines currently in PRIME scheme

8 May 2026

Human medicines European public assessment report (EPAR): Olanzapine Glenmark Europe, olanzapine, Date of authorisation: 03/12/2009, Revision: 15, Status: Authorised

8 May 2026

Human medicines European public assessment report (EPAR): Olanzapine Glenmark, olanzapine, Date of authorisation: 03/12/2009, Revision: 16, Status: Authorised

8 May 2026

Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate,umeclidinium,vilanterol, Date of authorisation: 15/11/2017, Revision: 14, Status: Authorised

8 May 2026

Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate,umeclidinium,vilanterol, Date of authorisation: 15/11/2017, Revision: 13, Status: Authorised

8 May 2026

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 73, Status: Authorised

8 May 2026